Afzoline XL 10 Drug Interactions

Concurrent use of mesoridazine, thioridazine, piperaquine, dronedarone, cisapride, pimozide, ziprasidone, bepridil, amifampridine, terfenadine, sparfloxacin, hydroxychloroquine, zuclopenthixol, fluoxetine, metronidazole, anagrelide, selected gonadotropin releasing hormone agonists, clozapine, escitalopram, moxifloxacin, dabrafenib, tizanidine, pasireotide, ivabradine, panobinostat, pitolisant, vinflunine, amiodarone, pimavanserin, tacrolimus, crizotinib, levofloxacin, quetiapine, aripiprazole, sevoflurane, delamanid, or bedaquiline and QT interval prolonging drugs may result in increased risk of QT interval prolongation.
Concurrent use of alfuzosin and ketoconazole, atazanavir, fosamprenavir, saquinavir, itraconazole, ritonavir, nelfinavir, idelalisib, boceprevir, telaprevir, tipranavir, indinavir, cobicistat, diltiazem, cyclosporine, delavirdine, erythromycin, nefazodone, voriconazole, imatinib, amprenavir, quinupristin/dalfopristin, or cimetidine may result in an increased alfuzosin plasma concentrations.
Concurrent use of alfuzosin and lopinavir/ritonavir, fluconazole, protriptyline, amoxapine, or toremifene may result in an increase in alfuzosin exposure and result in an increased risk of torsades de pointes.
Concurrent use of alfuzosin and posaconazole, telithromycin, clarithromycin, salmeterol, granisetron, azithromycin, trimipramine, astemizole, perflutren lipid microsphere, chlorpromazine, dasatinib, clomipramine, gatifloxacin, trifluoperazine, flecainide, propafenone, vandetanib, ranolazine, mefloquine, telavancin, trazodone, domperidone, ciprofloxacin, sodium phosphate, ondansetron, pazopanib, haloperidol, dofetilide, ofloxacin, lapatinib, asenapine, ibutilide, fingolimod, apomorphine, chloroquine, sorafenib, paliperidone, gemifloxacin, artemether/lumefantrine, tetrabenazine, nortriptyline, disopyramide, prochlorperazine, citalopram, procainamide, amitriptyline, desipramine, norfloxacin, quinine, quinidine, vemurafenib, imipramine, sunitinib, dolasetron, arsenic trioxide, promethazine, droperidol, solifenacin, iloperidone, or halofantrine may result in increased alfuzosin plasma concentrations and an increased risk of QT interval prolongation.
Concurrent use of alfuzosin and darunavir may result in an increase in alfuzosin levels, thereby increasing the risk for serious and/or life-threatening reactions.
Concurrent use of amisulpride, or sulpiride and QT prolonging agents are contraindicated and may result in increased risk of torsade de pointes.
Concurrent use of alfuzosin and tadalafil may result in potentiation of hypotensive effects.
Concurrent use of donepezil and QT prolonging agents may result in increased risk of QT interval prolongation and torsade de pointes.
Concurrent use of nilotinib and selected CYP3A4 substrates that prolong the QT interval may result in increased exposure of CYP3A4 substrate and increased risk of QT interval prolongation.
Concurrent use of vardenafil or sildenafil and alpha₁-adrenergic blockers may result in potentiation of hypotensive effects.
Concurrent use of alpha₁-adrenergic blockers and beta-adrenergic blockers may result in an exaggerated hypotension response to first dose of the alpha-blocker.
Concurrent use of alfuzosin and avanafil may result in increased risk of hypotension.
Concurrent use of yohimbine, or ma huang and alpha₁-adrenergic blockers may result in reduced effectiveness of alpha₁-adrenergic blockers.